SIZE XSSIZE SMSIZE MDSIZE LG

BCOP Annual Conference On-Demand

Were you unable to attend the HOPA Annual Conference?
Did you miss the opportunity to purchase the HOPA Virtual Conference?
Do you still need BCOP credits?
HOPA has the answer for you!

Advanced level oncology pharmacists seeking quality educational opportunities to meet their Board Certified Oncology Pharmacy (BCOP) recertification requirements will find the 2018 BCOP Annual Conference sessions a great option. Participants can earn up to 8 credit hours toward BCOP and/or Accreditation Council for Pharmacy credit.

Originally presented at the HOPA Annual Conference, the following session recordings are available:

ACBC1 – New Oncology Clinical Trial Designs: What Works?

ACBC2 – Updates in the Management of Urothelial Carcinoma

ACBC3 – Management of CAR-T Cell Adverse Effects in Hematologic Malignances

ACBC4 – Physician Aid and Dying (PAD): A Palliative Care Pharmacist’s Approach and Death with Dignity: Implications for Pharmacists

ACBC5 – Current and Novel Therapies for the Treatment of Neuroblastoma in Pediatric Patients

ACBC6 – Update on Head and Neck Cancer: Current Knowledge on Molecular Features and Emerging Novel Therapies

ACBC7 – Evolving Treatment Options for Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Pharmacist’s Perspective

Each session will involve a recording of the speaker presenting their topic, a pre-test and post-test.

 

HOPA Member Price: $225
Non-Member Price: $325

Purchase Now

Can be purchased as part of the 2018 BCOP Program Bundle

Activity type:

Application.

Accreditation Statement:

 logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. BCOP test must be completed by August 24, 2018.

education speaker bpslogo The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Test must be completed by August 24, 2018.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.


Sessions

ACBC1 - New Oncology Clinical Trial Designs: What Works?  

Description: This session will provide an overview of the limitations of traditional clinical trial designs used in oncology for the evaluation of personalized medicine and targeted therapies. Newer trial designs for these strategies will be presented, including umbrella and basket trials, along with a discussion of clinical outcome assessment, model-based phase 1 trials, and biomarker-based designs. Advantages and disadvantages of these designs will be assessed, and other trial designs may be included if time permits. The intended audience is clinical oncology pharmacists and academicians whose role includes the design or interpretation of clinical trials to improve the therapeutic outcomes of their patients.

Learning Objectives

  • Identify the limitations of traditional clinical trial designs used in oncology for the evaluation of personalized medicine and targeted therapies
  • Describe the methodology, strengths, and limitations of new oncology bio-marker-based trial designs, specifically basket and umbrella trials
  • Interpret results of basket and umbrella designs, as they relate to optimizing patient care

 Janelle Perkins

Janelle Perkins, PharmD BCOP
Dr. Perkins received her BSPharm from University of Florida and her PharmD from University of North Carolina. She completed an oncology specialty residency at the VA Hospital in San Antonio TX, then worked as a clinical pharmacist Moffitt Cancer Center. She then transitioned to a faculty member in the BMT Program. She is a co-investigator on numerous clinical trials, and a principal investigator on two funded prospective interventional trials. Currently, she is an associate professor at the University of South Florida College of Pharmacy where she teaches Research Methods and Oncology Pharmacotherapeutics. She is a chairperson for the USF IRB.

Disclosure: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-034-H04-P.


ACBC2: Updates in the Management of Urothelial Carcinoma

Description: This session will cover treatment updates in the management of urothelial carcinoma and the role of immunotherapy. Treatment options for metastatic urothelial carcinoma (mUC) have been limited. In light of immunotherapies, options now include two programmed cell death-1 and three programmed death-ligand 1 (PDL-1) inhibitors in the locally advanced or metastatic setting—atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab. This session will provide a detailed overview outlining the efficacy data of these agents and considerations for prioritizing therapy. In addition, we will discuss safety data, PDL-1 testing, management, and the role of the pharmacist in using checkpoint inhibitors to treat mUC. This session will also briefly outline ongoing clinical trials using immunotherapies for urothelial carcinoma.

Learning Objectives

  • Describe the current management of urothelial carcinoma
  • Compare immunotherapeutic options for patients with advanced or metastatic urothelial carcinoma
  • Identify strategies used in the selection of treatments for patients with advanced or metastatic urothelial carcinoma

 Kirollos Hanna

Kirollos Hanna, PharmD BCOP BCPS
Dr. Hanna is a board certified hematology/oncology pharmacist at Mayo Clinic and the University of Minnesota Medical Center. His primary practice is focused in both the ambulatory and inpatient settings. He received his doctorate from Florida A&M University, completed a PGY1 residency at St. Thomas Hospital (Nashville, TN), and his PGY2 residency in oncology at St. Luke's Mountain States Tumor Institute (Boise, ID). Dr. Hanna is involved with numerous organizations including the Patient-Centered Outcomes Research Institute and the Aplastic Anemia and MDS International Foundation focusing heavily on patient engagement and patient-centered care in clinical trials and rare diseases.

Disclosure: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-035-H04-P.


ACBC3: Management of Chimeric Antigen Receptor T-Cells

Description: Chimeric antigen receptor (CAR) T-cell therapies newly approved by the U.S. Food and Drug Administration have a distinct side-effect profile, and many practitioners lack familiarity with management of these side effects. These treatments have the potential to improve survival outcomes over those associated with conventional chemotherapy for both adults and pediatric patients. This session aims to teach pharmacists how to adapt their monitoring and management of these patients in inpatient and outpatient settings, compared to patients receiving chemotherapy-based regimens. The efficacy data will be briefly discussed, along with an extensive review of the pathophysiology and management of cytokine release syndrome (CRS) as well as CAR-T-cell-related encephalopathy syndrome (CRES). A practical case-based discussion applying the limited data for monitoring and managing patients with CRS and CRES will help learners apply the concepts covered. Supportive care management of other non-CRS and non-CRES toxicities will be discussed. The session will conclude with a discussion of opportunities for interventions for pharmacists caring for patients undergoing CAR T-cell therapy and the logistical challenges of implementing CAR T-cell therapies.

Learning Objectives

  • Describe the efficacy and safety of Chimeric Antigen Receptor (CAR)-T cell therapies
  • Evaluate the signs and symptoms of cytokine release syndrome (CRS) and CAR-T cell related encephalopathy syndrome (CRES)
  • Categorize the onset of CAR-T cell toxicities following administration of CAR-T cells
  • Outline patient-specific supportive care interventions and monitoring plans for patients receiving CAR-T cell therapy

 Brandon R Shank

Brandon R. Shank, PharmD MPH BCOP CPH
Brandon Shank, PharmD MPH BCOP is a Clinical Pharmacy Specialist at the University of Texas MD Anderson Cancer Center. Dr. Shank received his Doctor of Pharmacy Degree from the Philadelphia College of Pharmacy. He completed a PGY1 Pharmacy Practice and PGY2 Oncology Pharmacy Residency at the Johns Hopkins Hospital. His practice area is inpatient and outpatient Lymphoma, Multiple Myeloma, and Stem Cell Transplantation. He has several abstracts and peer-reviewed publications in the area of oncology. He is a co-editor and author for Demystifying Drug Dosing in Obese Patients.

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.25 contact hour (.125 CEUs) under the ACPE universal activity number 0465-0000-18-036-H04-P.


ACBC4: Physician Aid and Dying (PAD): A Palliative Care Pharmacist's Approach; Death With Dignity: Implications for Pharmacists

Description: Physician-assisted suicide, also known as physician-assisted death or death with dignity, is a controversial topic for healthcare providers and patients alike. This session will discuss the origins of this practice and current experiences and will explore issues from the point of view of both patients and providers. Because pharmacists prepare the final prescription used by patients, their involvement will be a focus. For both palliative care practitioners and oncology pharmacists, multiple approaches to physician aid in dying (PAD) exist. This session will provide insights into and provide a method for exploring care for the patient seeking aid in dying. Are the patient’s symptoms well managed or not, and how can the practitioner address these symptoms in a time-limited fashion? If a patient’s suffering or perception of suffering at the end of life does not improve, then we consider their nonmodifiable reasons for requesting physician assistance, and their request progresses as defined within the laws of that state. We will discuss patients’ cases, reviewing modifiable and nonmodifiable reasons for a PAD request and including pharmacists’ involvement and the use of medications in both types.

Learning Objectives

  • Describe patient needs which may result in a request for physician assisted suicide
  • Identify alternative approaches to Physician-Aid-in-Dying (PAD) in the setting of palliative care and hospice in different situations
  • Analyze the medication management of patients interested in PAD
  • Compare the pharmacist’s role in supporting and educating patients in palliative care vs PAD
  • Describe patient needs which may result in a request for physician assisted suicide
  • Identify alternative approaches to Physician-Aid-in-dying (PAD) in the setting of palliative care and hospice in different situations
  • Analyze the medication management of patients interested in PAD
  • Compare the pharmacist’s role in supporting and educating patients in palliative care vs PAD

 Joseph Bubalo

Joseph Bublalo, PharmD BCOP BCPS
Joseph Bubalo, PharmD BCPS BCOP is an oncology pharmacotherapy specialist with Oregon Health & Science University (OHSU) and an Assistant Professor of Medicine with the Division of Hematology and Medical Oncology.  He has been active in the clinical care of oncology and HSCT patients for over 20 years and has received research grants investigating ways to improve the control of nausea and vomiting as well as a variety of other topics in supportive care and infectious disease.  He continues to look for ways to decrease the symptoms associated with antineoplastic and surgical therapies.

Disclosures: Spectrum – Consulting fees, Genentech – Consulting fees, Helsinn – Research support

 Rabia Atayee

Rabia Atayee, PharmD BCPS
Dr. Rabia Atayee is an Associate Clinical Professor at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences as a board certified pharmacotherapy specialists with a focus area in pain and palliative care medicine.  At UC San Diego Health, Dr. Atayee practices under a collaborative practice protocol with DEA prescribing authority with the palliative care team.  Dr. Atayee is also immediate past president of a newly formed national organization, Society of Palliative Care Pharmacist.  Dr. Atayee has given several presentations related to pain and palliative care in the setting of oncology.

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.25 contact hour (.125 CEUs) under the ACPE universal activity number 0465-0000-18-037-H04-P.


ACBC5: Overview of Interesting and Novel Therapies for the Treatment of Neuroblastoma in Pediatric Patients

Description: An overview of interesting and novel therapies for the treatment of neuroblastoma will be presented. The target audiences are providers who encounter pediatric oncology patients and those interested in learning novel approaches to solid tumor therapy. Therapies to be discussed include tandem autologous stem cell transplantation, targeted antibodies, radionucleotide therapy, and differentiating agents, as well as monoclonal antibody therapy, which has been developed and approved specifically for the treatment of neuroblastoma.

Learning Objectives

  • Describe the use of retinoids as an adjunct to chemotherapy in treating neuroblastoma (NBL)
  • Develop recommendations for appropriate supportive care and monitoring parameters for safe delivery of dinutuximab
  • Analyze the role of autologous and tandem autologous hematopoietic stem cell transplant (HSCT) for high risk neuroblastoma
  • Identify the role of radionuclides for the treatment of neuroblastoma in both upfront therapy and relapsed disease

Nicole Kaiser

Nicole A Kaiser, RPh BCOP
Nicole Kaiser is an inpatient hematology/oncology clinical pharmacy specialist practicing in the area of pediatric solid tumors and hematologic malignancies at Children's Hospital Colorado. Mrs. Kaiser is an Assistant Clinical Professor at Skaggs School of Pharmacy and Pharmaceutical Sciences- University of Colorado Anschutz Medical Campus. Mrs. Kaiser received her BS in pharmacy from the University of Wisconsin School of Pharmacy in 1998, followed by pharmacy practice residency at the University of Wisconsin Hospital and Clinics. She then went on to complete her PGY2 pediatric oncology pharmacy specialty residency at Children's Hospital Colorado in 2000.

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-038-H04-P.


ACBC6: Update on Head and Neck Cancer: Molecular Features and Emerging Novel Therapies

Description: Each year, an estimated 55,000 adults in the United States develop head and neck cancer. Recent advances in molecular biology, genetics, and sequencing technologies now provide a basis for the practice of precision medicine in the management of head and neck cancer. This session will focus on novel therapies for head and neck cancer, including anti–programmed death ligand-1 and anti–programmed cell death-1 agents, antitumor vaccines, and targeted therapies. It will also cover pertinent screening and prevention guidelines for these patients.

Learning Objectives

  • Describe the current screening guidelines and preventative measures for head and neck squamous cell carcinoma (HNSCC)
  • Identify the role of various signaling pathways involved in the development and progression of HNSCC
  • Analyze available data for the use of targeted therapies and immunotherapy in the management of HNSCC
  • Compare the various novel therapeutic options for the treatment of HNSCC

 Eve Segal

Eve Segal, PharmD BCOP
Eve Segal is a clinical oncology pharmacist at the University of Washington Medical Center/Seattle Cancer Care Alliance (SCCA) in Seattle, WA. Eve received her PharmD degree from Massachusetts College of Pharmacy and Health Sciences in Boston, MA. Since then, she has completed a general residency in pharmacy practice at Norwood Hospital in Norwood, MA and a specialty residency in oncology at St. Luke's Mountain States Tumor Institute in Boise, ID. Presently, Eve works throughout the outpatient oncology clinics at the SCCA, including the thoracic, head and neck clinics.

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.25 contact hour (.125 CEUs) under the ACPE universal activity number 0465-0000-18-039-H04-P.


ACBC7: Evolving Treatment Options for Newly Diagnosed and Relapsed or Refractory Multiple Myeloma: A Pharmacist’s Perspective

Description: Novel treatment options for multiple myeloma are emerging rapidly, resulting in unprecedented response rates even for relapsed or refractory disease. Optimal up-front multidrug treatment selection and subsequent therapy sequencing, however, remain unclear. This session will foster oncology pharmacists’ understanding of the various new drugs and combination regimens for multiple myeloma to aid them in making recommendations for treatment selection and sequencing. This session will also examine the pharmacist’s role in managing patients with multiple myeloma, including supportive care, specialty pharmacy services, and requirements for risk evaluation and mitigation strategies. Future advances in myeloma, including the role of personalized immunotherapy, will also be discussed.

Learning Objectives

  • Interpret evidence behind select treatment options for newly diagnosed and relapsed/refractory multiple myeloma
  • Analyze the optimal sequence of treatment options for patients with relapsed/refractory multiple myeloma
  • Identify the pharmacist’s role in the management of patients with newly diagnosed and relapsed/refractory multiple myeloma
  • Describe emerging treatments in the drug development pipeline for multiple myeloma

 E Bridget BKim

E. Bridget Kim, PharmD BCOP BCPS
Dr. Kim received her Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill in 2008. She completed a post-graduate Pharmacy Practice Residency at Boston Medical Center. She has worked at Massachusetts General Hospital (MGH) Cancer Center since 2009. Dr. Kim is currently a board-certified oncology pharmacist with a dedicated clinical practice in multiple myeloma. She serves on a number of committees at MGH. Her pharmacy interests include: clinical pharmacy practice advancement, precepting/mentorship, and leadership.

Disclosures: No financial relationships exist with commercial interests. 

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.25 contact hour (.125 CEUs) under the ACPE universal activity 0465-0000-18-040-H04-P.

 

 

 

xs
sm
md
lg